Press "Enter" to skip to content

New patent for Bristol-myers Squibb drug EVOTAZ

1
Copyright © DrugPatentWatch. Originally published at New patent for Bristol-myers Squibb drug EVOTAZ

Annual Drug Patent Expirations for EVOTAZ
Annual Drug Patent Expirations for EVOTAZ

Evotaz is a drug marketed by Bristol-myers Squibb and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge.

EVOTAZ drug price trends.

Drug patent litigation for EVOTAZ.

This drug has two hundred and thirty-seven patent family members in thirty-nine countries.

The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. One supplier is listed for this compound. Additional details are available on the atazanavir sulfate; cobicistat profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Bristol-myers Squibb drug EVOTAZ

Comments are closed.

Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

Do NOT follow this link or you will be banned from the site!